MaxCyte, Inc. (MXCT) News
Filter MXCT News Items
MXCT News Results
Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
---|---|---|---|---|---|---|---|---|---|
Loading, please wait... |
MXCT News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest MXCT News From Around the Web
Below are the latest news stories about MAXCYTE INC that investors may wish to consider to help them evaluate MXCT as an investment opportunity.
MaxCyte, Inc.'s (LON:MXCT) Intrinsic Value Is Potentially 72% Above Its Share PriceKey Insights MaxCyte's estimated fair value is UK£5.59 based on 2 Stage Free Cash Flow to Equity MaxCyte's UK£3.24... |
MaxCyte Announces Retirement of Board Member Art MandellROCKVILLE, Md., Dec. 22, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that Art Mandell has retired from his position as a member of the Board of Directors of MaxCyte effective December 31, 2024. Mr. Mandell has served on the Board since 2006 and has been an integral part of MaxC |
MaxCyte Announces Streamlined Operations and Raises 2024 Revenue GuidanceROCKVILLE, Md., Dec. 08, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced the completion of an internal operational review, initiated earlier this year following the appointment of Maher Masoud as President and Chief Executive Officer. This “bottom-up” review focused on optimizing ne |
This MaxCyte Insider Increased Their Holding In The Last YearLooking at MaxCyte, Inc.'s ( LON:MXCT ) insider transactions over the last year, we can see that insiders were net... |
MaxCyte Celebrates 25 Years of Innovation Driving Cell Engineering-Based TherapeuticsSince 1999, MaxCyte’s non-viral cell engineering innovations have helped launch pioneering cell and gene therapy projectsROCKVILLE, Md., Nov. 13, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, marks the 25th anniversary of its founding this year. Over the past quarter-century, the company has rem |
MaxCyte Inc (MXCT) Q3 2024 Earnings Call Highlights: Strong Core Revenue Growth Amidst Market ...MaxCyte Inc (MXCT) reports a 23% increase in core revenue and maintains a robust cash position, despite a decline in gross margin and drug discovery revenue. |
MaxCyte, Inc. (MXCT) Reports Q3 Loss, Tops Revenue EstimatesMaxCyte (MXCT) delivered earnings and revenue surprises of 15.38% and 8.85%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock? |
MaxCyte Reports Third Quarter 2024 Financial Results and Updates Full Year 2024 GuidanceROCKVILLE, Md., Nov. 06, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell therapeutics, today announced its financial results for the third quarter ended September 30, 2024, and updated its 2024 guidance. Third Quarter and Recent Highlights Total revenue of $8.2 million in the third quarter of 2024, an increase |
MaxCyte to Participate in Two Upcoming Investor ConferencesROCKVILLE, Md., Oct. 31, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics, today announced Company management will participate at two upcoming investor conferences. Stifel 2024 Healthcare ConferenceFireside Chat on Monday, November 18th at 10:55 AM ET Stephens Annual Investment ConferenceFires |
MaxCyte, Inc. (LON:MXCT) is largely controlled by institutional shareholders who own 65% of the companyKey Insights Significantly high institutional ownership implies MaxCyte's stock price is sensitive to their trading... |